ES2548437T3 - 8-[6-amino-3-piridil]xantinas sustituidas - Google Patents
8-[6-amino-3-piridil]xantinas sustituidas Download PDFInfo
- Publication number
- ES2548437T3 ES2548437T3 ES07796049.0T ES07796049T ES2548437T3 ES 2548437 T3 ES2548437 T3 ES 2548437T3 ES 07796049 T ES07796049 T ES 07796049T ES 2548437 T3 ES2548437 T3 ES 2548437T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- meoh
- pharmaceutically acceptable
- pyridyl
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title description 18
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 102
- 150000003839 salts Chemical class 0.000 claims abstract description 34
- 101150078577 Adora2b gene Proteins 0.000 claims description 18
- 241000124008 Mammalia Species 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 12
- 230000001575 pathological effect Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 208000006673 asthma Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 206010022489 Insulin Resistance Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010038923 Retinopathy Diseases 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 230000008485 antagonism Effects 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 230000003902 lesion Effects 0.000 claims description 3
- 238000013160 medical therapy Methods 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 230000010410 reperfusion Effects 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 342
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 162
- 238000004128 high performance liquid chromatography Methods 0.000 description 53
- 230000014759 maintenance of location Effects 0.000 description 51
- 238000005481 NMR spectroscopy Methods 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 238000005160 1H NMR spectroscopy Methods 0.000 description 19
- -1 glycolylarsanyl Chemical group 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 108050000203 Adenosine receptors Proteins 0.000 description 14
- 102000009346 Adenosine receptors Human genes 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000002378 acidificating effect Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 8
- 229940075420 xanthine Drugs 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 229960005305 adenosine Drugs 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002287 radioligand Substances 0.000 description 5
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 4
- DIVYESOURJTWDY-UHFFFAOYSA-N 8-(6-aminopyridin-3-yl)-3,7-dihydropurine-2,6-dione Chemical class C1=NC(N)=CC=C1C(N1)=NC2=C1C(=O)NC(=O)N2 DIVYESOURJTWDY-UHFFFAOYSA-N 0.000 description 4
- 102000055025 Adenosine deaminases Human genes 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- FFBDFADSZUINTG-UHFFFAOYSA-N DPCPX Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1CCCC1 FFBDFADSZUINTG-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229940095074 cyclic amp Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- RIRGCFBBHQEQQH-SSFGXONLSA-N (-)-n6-(2-phenylisopropyl)adenosine Chemical compound C([C@@H](C)NC=1C=2N=CN(C=2N=CN=1)[C@H]1[C@@H]([C@H](O)[C@@H](CO)O1)O)C1=CC=CC=C1 RIRGCFBBHQEQQH-SSFGXONLSA-N 0.000 description 2
- KYOSRONGDTVPDJ-NVQRDWNXSA-N (2r,3r,4s,5r)-2-(6-anilinopurin-9-yl)-5-(hydroxymethyl)-2-propan-2-yloxolane-3,4-diol Chemical compound C1=NC2=C(NC=3C=CC=CC=3)N=CN=C2N1[C@]1(C(C)C)O[C@H](CO)[C@@H](O)[C@H]1O KYOSRONGDTVPDJ-NVQRDWNXSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- FMEBIWNKYZUWFV-UHFFFAOYSA-N 6-chloropyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)N=C1 FMEBIWNKYZUWFV-UHFFFAOYSA-N 0.000 description 2
- BLHCMGRVFXRYRN-UHFFFAOYSA-N 6-hydroxynicotinic acid Chemical compound OC(=O)C1=CC=C(O)N=C1 BLHCMGRVFXRYRN-UHFFFAOYSA-N 0.000 description 2
- 102000007470 Adenosine A2B Receptor Human genes 0.000 description 2
- 108010085273 Adenosine A2B receptor Proteins 0.000 description 2
- 206010049153 Allergic sinusitis Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 235000019797 dipotassium phosphate Nutrition 0.000 description 2
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- SIQPXVQCUCHWDI-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=C1NC=N2 SIQPXVQCUCHWDI-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- PMUVNAUPWLXPSA-LSCFUAHRSA-N (2r,3r,4s,5r)-2-[6-[(4-aminophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC(N)=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 PMUVNAUPWLXPSA-LSCFUAHRSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- NVBKOLWIWXBQBM-UHFFFAOYSA-N 1-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-1-(2-methoxyethyl)-3-(3-methoxyphenyl)urea Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCOC)C(=O)NC=3C=C(OC)C=CC=3)NC=2C(=O)N1C1CC1 NVBKOLWIWXBQBM-UHFFFAOYSA-N 0.000 description 1
- YRUUFZKRHYCNKZ-UHFFFAOYSA-N 1-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-1-(2-methoxyethyl)-3-(4-methoxyphenyl)urea Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCOC)C(=O)NC=3C=CC(OC)=CC=3)NC=2C(=O)N1C1CC1 YRUUFZKRHYCNKZ-UHFFFAOYSA-N 0.000 description 1
- YNYLEWPVAKQSRJ-UHFFFAOYSA-N 1-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-1-(2-methoxyethyl)-3-[3-(trifluoromethyl)phenyl]urea Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCOC)C(=O)NC=3C=C(C=CC=3)C(F)(F)F)NC=2C(=O)N1C1CC1 YNYLEWPVAKQSRJ-UHFFFAOYSA-N 0.000 description 1
- YHQKEERZJRUIQU-UHFFFAOYSA-N 1-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-3-(3-fluorophenyl)-1-(2-methoxyethyl)urea Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCOC)C(=O)NC=3C=C(F)C=CC=3)NC=2C(=O)N1C1CC1 YHQKEERZJRUIQU-UHFFFAOYSA-N 0.000 description 1
- IPJLAGYROVYHDV-UHFFFAOYSA-N 1-cyclopropyl-3-propyl-8-[6-(2-pyrrolidin-1-ylethylamino)pyridin-3-yl]-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(NCCN4CCCC4)=CC=3)NC=2C(=O)N1C1CC1 IPJLAGYROVYHDV-UHFFFAOYSA-N 0.000 description 1
- HXKWXZFMPSMNLP-UHFFFAOYSA-N 1-cyclopropyl-8-[6-(2-methoxyethylamino)pyridin-3-yl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(NCCOC)=CC=3)NC=2C(=O)N1C1CC1 HXKWXZFMPSMNLP-UHFFFAOYSA-N 0.000 description 1
- PTMVIFLCOAWKDU-UHFFFAOYSA-N 1-cyclopropyl-8-[6-(2-morpholin-4-ylethylamino)pyridin-3-yl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(NCCN4CCOCC4)=CC=3)NC=2C(=O)N1C1CC1 PTMVIFLCOAWKDU-UHFFFAOYSA-N 0.000 description 1
- ABLYHJCPXKGLHB-UHFFFAOYSA-N 1-cyclopropyl-8-[6-(2-piperidin-1-ylethylamino)pyridin-3-yl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(NCCN4CCCCC4)=CC=3)NC=2C(=O)N1C1CC1 ABLYHJCPXKGLHB-UHFFFAOYSA-N 0.000 description 1
- CPAFOHDUXCUDBQ-UHFFFAOYSA-N 1-cyclopropyl-8-[6-(methylamino)pyridin-3-yl]-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(NC)=CC=3)NC=2C(=O)N1C1CC1 CPAFOHDUXCUDBQ-UHFFFAOYSA-N 0.000 description 1
- DBGGSEKQTLEJGF-HRNJKAHLSA-N 2-[(2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]-n-ethyl-2-hydroxyacetamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(O)C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 DBGGSEKQTLEJGF-HRNJKAHLSA-N 0.000 description 1
- RNIUHIHTGPHJEN-AWEZNQCLSA-N 2-[(3S)-1-[2-(3,4-dichlorophenyl)acetyl]piperidin-3-yl]oxy-6-(trifluoromethyl)pyridine-4-carbonitrile Chemical compound ClC=1C=C(C=CC=1Cl)CC(=O)N1C[C@H](CCC1)OC=1C=C(C#N)C=C(N=1)C(F)(F)F RNIUHIHTGPHJEN-AWEZNQCLSA-N 0.000 description 1
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- RXTRRIFWCJEMEL-UHFFFAOYSA-N 2-chloropyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1Cl RXTRRIFWCJEMEL-UHFFFAOYSA-N 0.000 description 1
- LKBNSVXCQUYDHE-UHFFFAOYSA-N 3-(3-chlorophenyl)-1-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-1-(2-methoxyethyl)urea Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCOC)C(=O)NC=3C=C(Cl)C=CC=3)NC=2C(=O)N1C1CC1 LKBNSVXCQUYDHE-UHFFFAOYSA-N 0.000 description 1
- BSWAUSLWMYZKFT-UHFFFAOYSA-N 3-benzyl-1-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-1-(2-methoxyethyl)urea Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCOC)C(=O)NCC=3C=CC=CC=3)NC=2C(=O)N1C1CC1 BSWAUSLWMYZKFT-UHFFFAOYSA-N 0.000 description 1
- 125000003853 4-amino-3-iodobenzyl group Chemical group [H]N([H])C1=C(I)C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- LFXCYVITBNVTHL-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(Cl)N=C1 LFXCYVITBNVTHL-UHFFFAOYSA-N 0.000 description 1
- GQCSDHOYOQQJFJ-UHFFFAOYSA-N 8-(6-chloropyridin-3-yl)-1-cyclopropyl-3-propyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(Cl)=CC=3)NC=2C(=O)N1C1CC1 GQCSDHOYOQQJFJ-UHFFFAOYSA-N 0.000 description 1
- YITUHJOCTFWXRO-UHFFFAOYSA-N 8-(6-piperazin-1-ylpyridin-3-yl)-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N1CCNCC1 YITUHJOCTFWXRO-UHFFFAOYSA-N 0.000 description 1
- VTBPXOAZMUHOPB-UHFFFAOYSA-N 8-[6-(2-methoxyethylamino)pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CC=C(NCCOC)N=C1 VTBPXOAZMUHOPB-UHFFFAOYSA-N 0.000 description 1
- YLAXJSABKBJGAR-UHFFFAOYSA-N 8-[6-[[2-(6-fluoropyridin-3-yl)-2-oxoethyl]amino]pyridin-3-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1NCC(=O)C1=CC=C(F)N=C1 YLAXJSABKBJGAR-UHFFFAOYSA-N 0.000 description 1
- 101150007969 ADORA1 gene Proteins 0.000 description 1
- 101150051188 Adora2a gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- UIAYVIIHMORPSJ-UHFFFAOYSA-N N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide Chemical compound C=1C=C2NC(=O)C=CC2=CC=1OCCCC(=O)N(C)C1CCCCC1 UIAYVIIHMORPSJ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 240000007591 Tilia tomentosa Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- KDSYNTPPPISIJB-UHFFFAOYSA-N [3-[[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxymethyl]phenyl]-(3-fluoro-4-hydroxypyrrolidin-1-yl)methanone Chemical compound NCc1cc(OCc2cccc(c2)C(=O)N2CC(O)C(F)C2)nc(c1)C(F)(F)F KDSYNTPPPISIJB-UHFFFAOYSA-N 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- CAWBRCOBJNWRLK-UHFFFAOYSA-N acetyloxymethyl 2-[4-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-3-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]-5-methylphenoxy]ethoxy]phenyl]-1h-indole-6-carboxylate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C=2NC3=CC(=CC=C3C=2)C(=O)OCOC(C)=O)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O CAWBRCOBJNWRLK-UHFFFAOYSA-N 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 102000036109 cAMP binding proteins Human genes 0.000 description 1
- 108091010966 cAMP binding proteins Proteins 0.000 description 1
- 230000001275 ca(2+)-mobilization Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007958 cherry flavor Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229950002934 cilostamide Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- UFHFLCQGNIYNRP-JMRXTUGHSA-N ditritium Chemical compound [3H][3H] UFHFLCQGNIYNRP-JMRXTUGHSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- ZFKJVJIDPQDDFY-UHFFFAOYSA-N fluorescamine Chemical compound C12=CC=CC=C2C(=O)OC1(C1=O)OC=C1C1=CC=CC=C1 ZFKJVJIDPQDDFY-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- MBAWLMGZGHJFFH-UHFFFAOYSA-N n-(cyclopropylmethyl)-n-[5-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)pyridin-2-yl]-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N(C(=O)C=1C=NC(=CC=1)C(F)(F)F)CC1CC1 MBAWLMGZGHJFFH-UHFFFAOYSA-N 0.000 description 1
- FYLDASFZWPRPKG-UHFFFAOYSA-N n-(cyclopropylmethyl)-n-[5-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)pyridin-2-yl]pyridine-3-carboxamide Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N(C(=O)C=1C=NC=CC=1)CC1CC1 FYLDASFZWPRPKG-UHFFFAOYSA-N 0.000 description 1
- JXLGRZPQENQESK-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-6-fluoro-n-(2-methoxyethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCOC)C(=O)C=3C=NC(F)=CC=3)NC=2C(=O)N1C1CC1 JXLGRZPQENQESK-UHFFFAOYSA-N 0.000 description 1
- KDGNMPXFLDOSCJ-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-6-fluoro-n-(2-morpholin-4-ylethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCN3CCOCC3)C(=O)C=3C=NC(F)=CC=3)NC=2C(=O)N1C1CC1 KDGNMPXFLDOSCJ-UHFFFAOYSA-N 0.000 description 1
- NGBODMODYKSGJK-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-6-fluoro-n-(2-piperidin-1-ylethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCN3CCCCC3)C(=O)C=3C=NC(F)=CC=3)NC=2C(=O)N1C1CC1 NGBODMODYKSGJK-UHFFFAOYSA-N 0.000 description 1
- ZMVGWXIDFDHBEW-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-6-fluoro-n-methylpyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(C)C(=O)C=3C=NC(F)=CC=3)NC=2C(=O)N1C1CC1 ZMVGWXIDFDHBEW-UHFFFAOYSA-N 0.000 description 1
- DPZGVJCSPVXRGA-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(2-methoxyethyl)-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCOC)C(=O)C=3C=NC(=CC=3)C(F)(F)F)NC=2C(=O)N1C1CC1 DPZGVJCSPVXRGA-UHFFFAOYSA-N 0.000 description 1
- XHUXYWGVEDLOHD-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(2-methoxyethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCOC)C(=O)C=3C=NC=CC=3)NC=2C(=O)N1C1CC1 XHUXYWGVEDLOHD-UHFFFAOYSA-N 0.000 description 1
- PSKHJRCOGMNTIJ-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(2-methylpropyl)-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CC(C)C)C(=O)C=3C=NC(=CC=3)C(F)(F)F)NC=2C(=O)N1C1CC1 PSKHJRCOGMNTIJ-UHFFFAOYSA-N 0.000 description 1
- WPHPJRSLYHUQMF-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(2-morpholin-4-ylethyl)-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCN3CCOCC3)C(=O)C=3C=NC(=CC=3)C(F)(F)F)NC=2C(=O)N1C1CC1 WPHPJRSLYHUQMF-UHFFFAOYSA-N 0.000 description 1
- SFKYJARCXIZGGJ-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(2-morpholin-4-ylethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCN3CCOCC3)C(=O)C=3C=NC=CC=3)NC=2C(=O)N1C1CC1 SFKYJARCXIZGGJ-UHFFFAOYSA-N 0.000 description 1
- XVODBXXWRFVSDB-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(2-piperidin-1-ylethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCN3CCCCC3)C(=O)C=3C=NC=CC=3)NC=2C(=O)N1C1CC1 XVODBXXWRFVSDB-UHFFFAOYSA-N 0.000 description 1
- LMBZNEFPONTPFY-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(2-pyrrolidin-1-ylethyl)-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CCN3CCCC3)C(=O)C=3C=NC(=CC=3)C(F)(F)F)NC=2C(=O)N1C1CC1 LMBZNEFPONTPFY-UHFFFAOYSA-N 0.000 description 1
- NLRZJZBQZLEGQQ-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(cyclopropylmethyl)-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CC3CC3)C(=O)C=3C=NC(=CC=3)C(F)(F)F)NC=2C(=O)N1C1CC1 NLRZJZBQZLEGQQ-UHFFFAOYSA-N 0.000 description 1
- ZDGGEBFIUSOGIG-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(cyclopropylmethyl)-6-fluoropyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CC3CC3)C(=O)C=3C=NC(F)=CC=3)NC=2C(=O)N1C1CC1 ZDGGEBFIUSOGIG-UHFFFAOYSA-N 0.000 description 1
- PGYMWYPJXLEUOP-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(cyclopropylmethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CC3CC3)C(=O)C=3C=NC=CC=3)NC=2C(=O)N1C1CC1 PGYMWYPJXLEUOP-UHFFFAOYSA-N 0.000 description 1
- PEIWTQUETYAZAY-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-(thiophen-2-ylmethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CC=3SC=CC=3)C(=O)C=3C=NC=CC=3)NC=2C(=O)N1C1CC1 PEIWTQUETYAZAY-UHFFFAOYSA-N 0.000 description 1
- CSFFWYAJGSGTSH-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-ethyl-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CC)C(=O)C=3C=NC(=CC=3)C(F)(F)F)NC=2C(=O)N1C1CC1 CSFFWYAJGSGTSH-UHFFFAOYSA-N 0.000 description 1
- WULKGVCEOREGQF-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-ethylpyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(CC)C(=O)C=3C=NC=CC=3)NC=2C(=O)N1C1CC1 WULKGVCEOREGQF-UHFFFAOYSA-N 0.000 description 1
- IKIXRBGOWUFFBN-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-methyl-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(C)C(=O)C=3C=NC(=CC=3)C(F)(F)F)NC=2C(=O)N1C1CC1 IKIXRBGOWUFFBN-UHFFFAOYSA-N 0.000 description 1
- RLARTAXULBXIJY-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-propyl-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1C=C(C=2NC=3C(=O)N(C4CC4)C(=O)N(CCC)C=3N=2)C=NC=1N(CCC)C(=O)C1=CC=C(C(F)(F)F)N=C1 RLARTAXULBXIJY-UHFFFAOYSA-N 0.000 description 1
- YSWIMYHCXWNYSL-UHFFFAOYSA-N n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]-n-propylpyridine-3-carboxamide Chemical compound C=1C=C(C=2NC=3C(=O)N(C4CC4)C(=O)N(CCC)C=3N=2)C=NC=1N(CCC)C(=O)C1=CC=CN=C1 YSWIMYHCXWNYSL-UHFFFAOYSA-N 0.000 description 1
- ZSUISVYQPCQFIR-UHFFFAOYSA-N n-[5-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)pyridin-2-yl]-6-fluoro-n-(2-methoxyethyl)pyridine-3-carboxamide Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N(CCOC)C(=O)C1=CC=C(F)N=C1 ZSUISVYQPCQFIR-UHFFFAOYSA-N 0.000 description 1
- UCJHFBRLBXCMCB-UHFFFAOYSA-N n-[5-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)pyridin-2-yl]-6-fluoro-n-methylpyridine-3-carboxamide Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N(C)C(=O)C1=CC=C(F)N=C1 UCJHFBRLBXCMCB-UHFFFAOYSA-N 0.000 description 1
- QGIHZFBBVFWEGA-UHFFFAOYSA-N n-[5-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)pyridin-2-yl]-n-(2-methoxyethyl)-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N(CCOC)C(=O)C1=CC=C(C(F)(F)F)N=C1 QGIHZFBBVFWEGA-UHFFFAOYSA-N 0.000 description 1
- BUVPOIGYEWVPGS-UHFFFAOYSA-N n-[5-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)pyridin-2-yl]-n-ethyl-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=N1)=CC=C1N(CC)C(=O)C1=CC=C(C(F)(F)F)N=C1 BUVPOIGYEWVPGS-UHFFFAOYSA-N 0.000 description 1
- HBPYKPOETSXYFP-UHFFFAOYSA-N n-cyclopropyl-n-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-7h-purin-8-yl)pyridin-2-yl]pyridine-3-carboxamide Chemical compound O=C1N(CCC)C=2N=C(C=3C=NC(=CC=3)N(C3CC3)C(=O)C=3C=NC=CC=3)NC=2C(=O)N1C1CC1 HBPYKPOETSXYFP-UHFFFAOYSA-N 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80503006P | 2006-06-16 | 2006-06-16 | |
| US805030P | 2006-06-16 | ||
| US80556406P | 2006-06-22 | 2006-06-22 | |
| US805564P | 2006-06-22 | ||
| US11/811,823 US7884100B2 (en) | 2006-06-16 | 2007-06-12 | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US811823 | 2007-06-12 | ||
| PCT/US2007/013849 WO2007149277A2 (en) | 2006-06-16 | 2007-06-13 | Substituted 8-[6-amino-3-pyridyl]xanthines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2548437T3 true ES2548437T3 (es) | 2015-10-16 |
Family
ID=56290980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07796049.0T Active ES2548437T3 (es) | 2006-06-16 | 2007-06-13 | 8-[6-amino-3-piridil]xantinas sustituidas |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7884100B2 (enExample) |
| EP (1) | EP2029143B1 (enExample) |
| JP (1) | JP5417558B2 (enExample) |
| KR (1) | KR101413404B1 (enExample) |
| CN (1) | CN103145712A (enExample) |
| AU (1) | AU2007261568B2 (enExample) |
| BR (1) | BRPI0712001B8 (enExample) |
| CA (1) | CA2655598C (enExample) |
| DK (1) | DK2029143T3 (enExample) |
| EA (1) | EA016791B1 (enExample) |
| ES (1) | ES2548437T3 (enExample) |
| HU (1) | HUE026457T2 (enExample) |
| IL (1) | IL195916A (enExample) |
| MX (1) | MX2008015954A (enExample) |
| MY (1) | MY152178A (enExample) |
| NZ (1) | NZ597222A (enExample) |
| PL (1) | PL2029143T3 (enExample) |
| PT (1) | PT2029143E (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| RU2357969C2 (ru) * | 2003-08-25 | 2009-06-10 | АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи | Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе |
| WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| US7579348B2 (en) * | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| WO2006091936A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| US7884100B2 (en) | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| WO2022246392A1 (en) | 2021-05-18 | 2022-11-24 | Purnovate, Inc. | Cyclic amide-containing pyridyl xanthines as a 2b antagonists |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6060481A (en) | 1998-05-28 | 2000-05-09 | The Penn State Research Foundation | Method for improving insulin sensitivity using an adenosine receptor antagonist |
| GB9817623D0 (en) | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| KR20030031466A (ko) * | 2000-02-17 | 2003-04-21 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 포유동물 세포 증식을 조절하기 위한 ａ２ｂ 아데노신수용체 길항 물질의 동정 및 사용 방법 |
| US7317017B2 (en) * | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| NZ532816A (en) | 2001-11-09 | 2005-11-25 | Cv Therapeutics Inc | A2B adenosine receptor antagonists |
| US6977300B2 (en) | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| KR20040080939A (ko) | 2002-02-01 | 2004-09-20 | 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 | 8-헤테로아릴 크산틴 아데노신 에이투비 수용체 길항제 |
| US7034070B2 (en) * | 2002-09-27 | 2006-04-25 | Vincent Chuang | Arylalkyl aminofunctional silanes for epoxy laminates |
| US7148229B2 (en) | 2003-02-19 | 2006-12-12 | Hoffman-La Roche Inc. | Sulfonamide substituted xanthine derivatives |
| RU2357969C2 (ru) | 2003-08-25 | 2009-06-10 | АДЕНОЗАЙН ТЕРАПЬЮТИКС, ЭлЭлСи | Новые замещенные 8-гетероарилксантины и фармацевтическая композиция на их основе |
| ES2387653T3 (es) | 2004-09-01 | 2012-09-27 | Gilead Sciences, Inc. | Procedimiento de cicatrización de heridas utilizando antagonistas del receptor de adenosina A2B |
| US20060053029A1 (en) | 2004-09-03 | 2006-03-09 | Butler Keith R | Methods and systems for providing an enterprise supply management portal |
| MX2007004373A (es) | 2004-10-15 | 2007-08-08 | Cv Therapeutics Inc | Metodo para prevenir y tratar el remoldeo de las vias respiratorias e inflamacion pulmonar utilizando antagonistas de receptor adenosina a2b. |
| US7601723B2 (en) * | 2005-02-25 | 2009-10-13 | Pgx Health, Llc | Pyridyl substituted xanthines |
| WO2006091898A2 (en) | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| US7579348B2 (en) * | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| WO2006091936A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| EP2301937A1 (en) | 2005-06-16 | 2011-03-30 | Cv Therapeutics, Inc. | Prodrugs of A2b adenosine receptor antagonists |
| WO2007109547A2 (en) * | 2006-03-17 | 2007-09-27 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| WO2007149115A1 (en) * | 2006-06-15 | 2007-12-27 | Targeted Genetics Corporation | Methods for treating target joints in inflammatory arthritis using aav vectors encoding a tnf antagonist |
| US7884100B2 (en) | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7767685B2 (en) | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| US7875608B2 (en) * | 2007-12-17 | 2011-01-25 | Thompson Robert D | Substituted 8-[6-amino-3pyridyl]xanthines |
| CA2718983C (en) | 2008-03-26 | 2015-12-08 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
-
2007
- 2007-06-12 US US11/811,823 patent/US7884100B2/en not_active Expired - Fee Related
- 2007-06-13 HU HUE07796049A patent/HUE026457T2/en unknown
- 2007-06-13 CA CA2655598A patent/CA2655598C/en active Active
- 2007-06-13 EA EA200900010A patent/EA016791B1/ru unknown
- 2007-06-13 BR BRPI0712001A patent/BRPI0712001B8/pt active IP Right Grant
- 2007-06-13 ES ES07796049.0T patent/ES2548437T3/es active Active
- 2007-06-13 MY MYPI20084937 patent/MY152178A/en unknown
- 2007-06-13 KR KR1020097000879A patent/KR101413404B1/ko active Active
- 2007-06-13 PL PL07796049T patent/PL2029143T3/pl unknown
- 2007-06-13 JP JP2009515468A patent/JP5417558B2/ja not_active Expired - Fee Related
- 2007-06-13 EP EP07796049.0A patent/EP2029143B1/en active Active
- 2007-06-13 PT PT77960490T patent/PT2029143E/pt unknown
- 2007-06-13 AU AU2007261568A patent/AU2007261568B2/en active Active
- 2007-06-13 MX MX2008015954A patent/MX2008015954A/es active IP Right Grant
- 2007-06-13 NZ NZ597222A patent/NZ597222A/xx unknown
- 2007-06-13 CN CN2013100513402A patent/CN103145712A/zh active Pending
- 2007-06-13 DK DK07796049.0T patent/DK2029143T3/en active
-
2008
- 2008-12-14 IL IL195916A patent/IL195916A/en active IP Right Grant
-
2010
- 2010-12-14 US US12/967,876 patent/US8258142B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0712001B1 (pt) | 2020-04-07 |
| DK2029143T3 (en) | 2015-09-21 |
| IL195916A (en) | 2015-06-30 |
| AU2007261568A1 (en) | 2007-12-27 |
| US20080004292A1 (en) | 2008-01-03 |
| EP2029143B1 (en) | 2015-07-08 |
| PL2029143T3 (pl) | 2015-12-31 |
| US8258142B2 (en) | 2012-09-04 |
| JP5417558B2 (ja) | 2014-02-19 |
| EP2029143A2 (en) | 2009-03-04 |
| CA2655598A1 (en) | 2007-12-27 |
| CA2655598C (en) | 2014-10-28 |
| US7884100B2 (en) | 2011-02-08 |
| HUE026457T2 (en) | 2016-05-30 |
| EA200900010A1 (ru) | 2009-10-30 |
| IL195916A0 (en) | 2009-09-01 |
| JP2010500284A (ja) | 2010-01-07 |
| KR20090029268A (ko) | 2009-03-20 |
| MX2008015954A (es) | 2009-03-06 |
| BRPI0712001B8 (pt) | 2021-05-25 |
| BRPI0712001A2 (pt) | 2012-01-10 |
| PT2029143E (pt) | 2015-10-20 |
| MY152178A (en) | 2014-08-15 |
| AU2007261568B2 (en) | 2013-05-16 |
| CN103145712A (zh) | 2013-06-12 |
| EP2029143A4 (en) | 2009-07-15 |
| US20110082139A1 (en) | 2011-04-07 |
| KR101413404B1 (ko) | 2014-06-27 |
| NZ597222A (en) | 2013-06-28 |
| EA016791B1 (ru) | 2012-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2548437T3 (es) | 8-[6-amino-3-piridil]xantinas sustituidas | |
| ES2440467T3 (es) | 8-heteroaril xantinas substituidas | |
| US7875608B2 (en) | Substituted 8-[6-amino-3pyridyl]xanthines | |
| WO2006091896A2 (en) | Pyridyl substituted xanthines | |
| US7470697B2 (en) | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | |
| WO2011005871A1 (en) | Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists | |
| CN101466382A (zh) | 取代的8-[6-氨基-3-吡啶基]黄嘌呤 | |
| HK1131569A (en) | Substituted 8-[6-amino-3-pyridyl]xanthines | |
| HK1096397B (en) | Substituted 8-heteroaryl xanthines | |
| HK1148518B (en) | Substituted 8-heteroaryl xanthines |